Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2017
Association of Tissue Abiraterone Levels and
Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
In one paragraph
Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 10% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- SLCO1B3 and SLCO2B1 genotypes, androgen deprivation therapy, and prostate cancer outcomes: a prospective cohort study and meta-analysis.Carcinogenesis · 2024Pooled it
- Statin Use and Survival Among Men Receiving Androgen-Ablative Therapies for Advanced Prostate Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial.Clinical pharmacokinetics · 2024Trial
- Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Trial
- Roles and therapeutic potential of the SLC family in prostate cancer-literature review.BMC urology · 2025Review
- Association of serum steroids with survival in metastatic hormone-sensitive prostate cancer.Endocrine-related cancer · 2025Article
- Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement.Clinical pharmacokinetics · 2023Article
- Genetic variations predicting progression with docetaxel and novel androgen-receptor pathway inhibitors.Cancer science · 2023Article
- Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.European urology open science · 2021Article
- Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p.Scientific reports · 2021Article
- Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.The Prostate · 2021Article
- Differential Associations of SLCO Transporters with Prostate Cancer Aggressiveness between African Americans and European Americans.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Article
- Article
- Genetic Polymorphisms and Pharmacotherapy for Prostate Cancer.JMA journal · 2021Review
- Determination of Intraprostatic and Intratesticular Androgens.International journal of molecular sciences · 2021Review
- Gene polymorphism-related differences in the outcomes of abiraterone for prostate cancer: a systematic overview.American journal of cancer research · 2021Review
- Article
- Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.The Journal of pharmacology and experimental therapeutics · 2020Article
- Review
- Association of prostate cancer SLCO gene expression with Gleason grade and alterations following androgen deprivation therapy.Prostate cancer and prostatic diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 4 institutions in 1 country.
Elahe A MostaghelFred Hutchinson Cancer Research Center, Seattle, Washington. emostagh@fhcrc.org.
Eunpi ChoPalo Alto Medical Foundation, Palo Alto, California.
Ailin ZhangFred Hutchinson Cancer Research Center, Seattle, Washington.
Mohammad AlyamaniLerner Research Institute, Glickman Urological and Kidney Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Arja KaipainenFred Hutchinson Cancer Research Center, Seattle, Washington.
Sean GreenFred Hutchinson Cancer Research Center, Seattle, Washington.
Brett T MarckGeriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington.
Nima SharifiLerner Research Institute, Glickman Urological and Kidney Institute, and Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Jonathan L WrightUniversity of Washington, Seattle, Washington.
Roman GulatiFred Hutchinson Cancer Research Center, Seattle, Washington.
Lawrence D TrueUniversity of Washington, Seattle, Washington.
Massimo LodaDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Alvin M MatsumotoGeriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington.
Daniel TamaePerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Trevor N PenningPerelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Steven P BalkBeth Israel Deaconess Medical Center, Boston, Massachusetts.
Phillip W KantoffMemorial Sloan Kettering Cancer Center, New York, New York.
Peter S NelsonFred Hutchinson Cancer Research Center, Seattle, Washington.
Mary-Ellen TaplinDana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
R Bruce MontgomeryUniversity of Washington, Seattle, Washington.
Fred Hutch Cancer Center · USUniversity of Washington · USDana-Farber Cancer Institute · USHarvard University · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1MTumor and Circulating Markers as Links Between Obesity and Lethal Prostate CanceP50CA090381 · NCI · DANA-FARBER CANCER INSTITUTE · PI KANTOFF, PHILIP W · 2002 to 2017
$36.2MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0MTRAINING IN CANCER BIOLOGY &TRANSPLANTATIONT32CA009515 · NCI · UNIVERSITY OF WASHINGTON · PI NANCY ELLEN DAVIDSON, Effie W Petersdorf · 1985 to 2026
$16.2MTraining Program in Cancer PharmacologyR25CA101871 · NCI · UNIVERSITY OF PENNSYLVANIA · PI BLAIR, IAN ALEXANDER · 2003 to 2013
$4.3MNCI NIH HHS P01 CA163227NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA090381NCI NIH HHS P50 CA097186NCI NIH HHS R25 CA101871NCI NIH HHS T32 CA009515
Abstract
PubMed holds no abstract for this paper.
Indexed as
Abiraterone AcetateAntineoplastic Combined Chemotherapy ProtocolsGenotypeGerm-Line MutationGonadotropin-Releasing HormoneHumansMaleOrganic Anion TransportersPolymorphism, Single NucleotidePrednisoneProstateProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantTestosteroneTreatment OutcomeAbiraterone AcetateGonadotropin-Releasing HormoneOrganic Anion TransportersPrednisoneProstate-Specific AntigenTestosterone
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.